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R ecruitment and retention of participants to clinical tri-als is critical to the outcome and success of clinicaltrial research. Clinical trials in nursing research have
become more prevalent in the past decade, particularly as
more intervention-level studies are implemented (Burns &
Grove, 1997). Clinical trials have provided validity to exami-
nations of outcomes of nursing interventions for testing
theory-based practice (Tyzenhouse, 1981; Woods, 1990).
Clinical trials in nursing fall into two categories—preven-
tive and therapeutic (Talbot, 1995). Preventive trials examine
the efficacy of a specific treatment in reducing risks associated
with a disease. Therapeutic trials examine outcomes of spe-
cific interventions or treatments, such as symptom relief, risk
reduction, or relapse prevention. The most common types of
clinical trials are drug studies that test the efficacy of medica-
tions.
An advantage of clinical trials is that they establish a rela-
tionship between treatment and clinical outcomes. Clinical
trials most often require randomization, which involves place-
ment of subjects in groups on a random basis, giving every
subject an equal chance of being assigned and eliminating
selection bias (Polit & Hungler, 1999). This method helps
reduce threats to internal and external validity (Talbot, 1995).
Disadvantages of clinical trials include expense and ethical
considerations related to treatments for which risks have not
yet been documented (Talbot).
A number of factors may affect participation in clinical tri-
als. Pilot studies are critical and usually required prior to the
implementation of large clinical trials. The pilot study allows
Key Points . . .
➤ Successful clinical trial participation can be increased when
barriers and issues are identified.
➤ Success in overcoming barriers related to subject recruit-
ment, retention, and compliance could result in decreased
costs and increase the power of the study.
➤ Successful clinical trials depend on study design, participant
factors, issues related to ethnic diversity, the informed con-
sent process, and physician factors.
➤ The model for successful participation identifies strategies
that can be used across disciplines by nurses and healthcare
providers to facilitate successful accrual and increased satis-
faction of patients, nurses, and physicians.
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The Process of Clinical Trials: A Model for
Successful Clinical Trial Participation
Cecile A. Lengacher, RN, PhD, Lois L. Gonzalez, PhD, ARNP, Rosemary Giuliano, ARNP,
MSN, Mary P. Bennett, DNSc, RN, Charles E. Cox, MD, and Douglas S. Reintgen, MD
Purpose/Objectives: To present barriers and strategies
related to successful clinical trial participation and inte-
grate them into a model for successful trial participation.
Data Sources: The proposed model was developed
based on a literature review related to clinical trial partici-
pation, review of empirical studies related to clinical trials,
and experiences with subject participation.
Data Synthesis: Successful clinical trial participation de-
pends on study design, participant factors, issues related to
ethnic diversity, the informed consent process, and physi-
cian factors.
Conclusions: Clinical trial participation is critical for all dis-
ciplines. However, nurses either are researchers or co-inves-
tigators with physicians on clinical trials, and it is critical for
them to understand specific barriers and success strategies
for patient participation. Future studies need to be con-
ducted related to participation in nursing clinical trial re-
search. These study results will facilitate successful nursing
clinical trials.
Implications for Nursing Practice: This model can be used
in implementation of clinical trials across disciplines prior to
and during enrollment of patients into studies.
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the opportunity to examine the intervention, methodology,
instruments, and processes of subject enrollment. Funding
agencies expect pilot data to anticipate and resolve issues,
which will make the large clinical trial successful (Burns &
Grove, 1997). Major issues in clinical trials often are related
to recruitment, accrual, retention, and compliance/adherence
of research subjects. Valid and reliable results from clinical
trials require large samples, usually from multiple sites and
multiple geographic locations. The costs of conducting clini-
cal trials generally are covered by extramural funds.
Success in overcoming barriers related to subject recruit-
ment, retention, and compliance/adherence decreases costs
and increases the power of the study (Agras & Bradford, 1982;
Hunninghake, Darby, & Probstfield, 1987; Tangrea, 1997).
The purpose of this article is to address the barriers and issues
related to successful clinical trials and to provide strategies for
improving clinical trial participation. A model for successful
trial participation has been developed that addresses barriers
and strategies.
Model Development
The proposed Model for Clinical Trial Participation (see
Figure 1) was developed based on a literature review and ex-
periences with subject participation. Analysis and use of the
model in implementation of clinical trials may be helpful in all
research disciplines. The model identifies barriers and issues
related to clinical trial participation, strategies that can be used
Figure 1. Model for Clinical Trial Participation
BARRIERS/ISSUES/CONCERNS
• Successful clinical trials,
within time frame





• Advancement of nursing/
medical science
• Readability of the con-
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• Supportive attitude by re-
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mary-care physician.
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• Give something back to
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for success, and outcomes for successful clinical trials. A lit-
erature review indicated that successful clinical trials depend
on certain key issues and factors: study design, participant
factors, issues related to ethnic diversity, the informed consent
process, and physician factors. Strategies for success are iden-
tified in the model to overcome these issues and concerns, and
specific outcomes are identified. Healthcare providers across
disciplines can use the model prior to and during enrollment
of patients into studies.
Literature Review
A literature review revealed specific barriers and factors
related to the success of clinical trials. The major barriers
identified were study design, participant factors (i.e., general
and personal issues related to special populations), the in-
formed consent process, and physician factors.
Study Design
Study design has been identified as a major factor in the
successful process of clinical trials. Clinical trials often are
dictated by the intervention or agent and the endpoint being
monitored. They most often are randomized and include an
experimental group that receives the intervention and a con-
trol group that receives standard care. Patients who want more
control and a greater role in their healthcare decisions are
somewhat less likely to volunteer for clinical trials because of
the nature of randomization to an intervention, which often is
double-blind, with no feedback occurring until the trial is over
(Winn, 1994). Patients who believe their needs should have a
high priority may not agree with this. The very fact of be-
ing randomized may cause uncertainty with the process
(Winn).
Because randomization frequently is a critical part of a
clinical trial, the overall study design must include strategies
to overcome patients’ reluctance to participate in a random-
ized study. Clear explanation of the randomization process
and the role of the control group is needed so patients do not
feel that something has gone wrong if they do not receive the
experimental treatment. In addition, offering patients who are
randomized to the control group some benefit (e.g., being first
to receive the experimental treatment following the study)
also can help. For instance, in a randomized control study of
the effects of massage on immune function, subjects who
were randomized to the control group (no massage) were of-
fered free massage therapy following the study (Bennett,
Fletcher, Barnhart, Hudgins, & Sims, 2000).
Trials that have clear, simple goals and endpoints based on
a defined rationale have a greater chance of success (Tangrea,
1997). Sometimes, researchers are tempted to include ancil-
lary studies and additional interventions or collections of bio-
logic specimens to test other hypotheses (Tangrea). This in-
creased complexity can be a barrier to nurse, physician, and
patient participation (Hjorth, Holmberg, Rodjer, Taube, &
Westin, 1996; Mansour, 1994). A more complex design in-
creases the requirement for a more complex infrastructure to
carry out the study. If a need or desire to conduct multisite
studies exists, the impact on the primary goals should be ex-
amined. Complex studies often have multiple inclusion or
exclusion criteria that can limit patient eligibility. This can
discourage nurses and physicians from enrolling patients into
a study.
Participant Factors
General participant factors: Age, serious illness and
comorbid conditions, level of education, and perception of ben-
efits can influence successful trial participation.
A major risk factor for certain illnesses is age. Because of
increased longevity, more people are developing serious ill-
nesses. Potential barriers to clinical trial participation in older
patients include history of prior malignancy, more frequent and
serious comorbid conditions, presentation of an advanced stage,
poor knowledge resulting from less education, and the percep-
tion that older patients are less likely to benefit from research
(Trimble et al., 1994). Including older women, assessing for
comorbid conditions, and identifying individuals to be targeted
for special assistance programs that focus on adherence can
assist with clinical trial participation (Buist et al., 2000). Older
patients may lack financial, social, and logistic support for par-
ticipation (Trimble et al.). Statistics show an increase in cancer
in patients over age 65, yet participation in trials by those over
age 65 is not common (Reis, Hankey, & Edwards, 1990;
Yancik & Reis, 1994). A need exists to examine how age can
affect participation in these trials.
Another problem is the lack of older female participants in
clinical trials (Muss, 1996). In a current trial at a regional can-
cer institute, one factor that often is a problem for older women
is transportation to the hospital to complete the protocol or in-
terventions related to the trial. Often, older women do not drive,
are not physically able to travel, or do not have a husband or
family member to transport them. They also may lack access to
or be uncomfortable using public transportation. In addition, if
traveling to the hospital for participation in studies is costly,
they may not be able to afford to return (Lengacher, 2000).
Oncologists had greater expectations of benefits from clini-
cal trials than were found in the literature related to phase I
trials (Daugherty et al., 1995). Participants’ tendency to over-
estimate their chances of cure with a particular treatment or
the potential benefits from enrollment (Kodish, Stocking,
Ratain, Kohrman, & Siegler, 1992) is another issue. Often, pa-
tients’ and physicians’ expectations are similar, although
therapeutic benefit is not guaranteed (Daugherty et al.). Pa-
tients with cancer and parents of children with cancer were
found to have an expectation of benefit similar to their phy-
sicians (Lesko, Dermatis, Penman, & Holland, 1989).
Personal participant factors: Other barriers identified
were costs to patients, control, altruism, fear of risk, desire for
privacy, lack of family support, transportation, socioeconomic
status, time off from work, extra procedures, or unwillingness
to tolerate toxicity (Bevan, Chee, McGhee, & McInnes, 1993;
Hudmon et al., 1996; Mattson, Curb, & McArdle, 1985; Novak,
Seckman, & Stewart, 1977; Tangrea, Adrianza, & Helsel, 1992;
Winn, 1994). In a study of patients’ perceptions of participation
in a phase I cancer trial, the barrier that was considered most
difficult was problems with billing (patients were billed in er-
ror for participation). Only 22% of participants indicated that
they would be willing to pay for participation in the study
(Hudmon et al.). Related to costs and problems with accrual
are transportation problems. Similar to the barriers for older
female participants, cost and transportation are problems for
accrual. Travel time, cost of travel, methods of transportation,
and traveling with others can affect costs and trial enrollment
(Hudmon et al.). These factors are especially critical for pa-
tients of lower economic status or those without insurance.
ONF – VOL 28, NO 7, 2001
1118
Studies also have found that a primary motivation corre-
lated with participation is patients’ altruism—their belief that
they would be contributing to increasing medical knowledge
(Bevan et al., 1993; Tangrea et al., 1992) or preventing oth-
ers from getting cancer in the future (Hudmon et al., 1996). In
addition, adherence and compliance issues occur with clinical
trial participation. Careful screening for motivation and abil-
ity to participate is critical. Patients who have doubts should
not be enrolled (Fleetwood, 1993). Adherence and compli-
ance decline with a complex intervention over a long duration.
Tailoring the regimen to the patients’ lifestyles as much as
possible is helpful (Tangrea, 1997).
Ethnically diverse patients: Another very critical issue is
increasing the number of ethnically diverse patients involved
in clinical trials. Typical clinical trial participants are white,
have higher levels of education, are in the middle-to-upper
socioeconomic class, and are male. Increased participation by
women from diverse groups is an important goal. Identified
barriers to minority participation are historical; economic; so-
cial and cultural issues; availability, affordability, accessibility,
and acceptability of clinical trials for minorities (McCabe,
Varricchio, & Padberg, 1994; Thomas, Pinto, Roach, &
Vaughn, 1994); and research (Swanson & Ward, 1995).
Although African Americans have the highest age-adjusted
incidence of cancer and mortality rates in the United States,
they remain underrepresented in prevention and control stud-
ies (Paskett, DeGraffinreid, Tatum, & Margitic, 1996). His-
torical incidents perpetuate mistrust and fear among African
Americans related to clinical research. This mistrust is not
only a product of the patient population, but also of African
American physicians who often fail to refer patients for clini-
cal trials (McCaskil-Stevens et al., 1999). In a study of percep-
tions of African American women about participation in clini-
cal trials, 29% felt that researchers did not care about them
compared to 14% of white women surveyed. Only 28% of the
African American women felt that the research was ethical
(Mouton, Harris, Rovi, Solorzano, & Johnson, 1997).
Informed Consent
Many factors are related to informed consent. Level of edu-
cation is a factor in comprehension and recall of information
(Cassileth, Zupkis, Sutton-Smith, & March, 1980; Daugherty
et al., 1995; Lawson & Adamson, 1995; Riecken & Ravich,
1982; Waggoner & Sherman, 1996). Serious illness adversely
affects comprehension in both younger and older patients
(Stanley, Guido, Staley, & Shortell, 1984).
According to Daugherty et al. (1995), level of education
was a predictor of the ability of patients with cancer to recall
the purpose of the trial. Although patients were able to under-
stand information about the clinical trial, only one-third could
remember the purpose. The reading level of the informed
consent document can be critical (Meade, 1999). Other re-
searchers found that patients with less than a high school edu-
cation had a more difficult time recalling information about
the trial and specific information in the consent form (Cassi-
leth et al., 1980).
Patients’ physiologic illnesses can have an accompanying
psychological response that makes them less able or willing
to understand the information obtained in the informed con-
sent process (Taylor, 1999). Healthy volunteers were found to
retain the most information compared to patients with serious
illnesses (Schaeffer et al., 1996). Perception of the treatment
and benefits affects participation. Patients with cancer may
perceive enrollment in a research protocol as a last hope to re-
ceive effective treatment (Schaeffer et al.).
The Informed Consent Process
A number of informed consent process-centered factors
have been identified: timing (when the discussion takes
place), readability of the consent form, content of the consent
form, and who assists the patient through the process (Taylor,
1999). Timing of approach to the trial has an impact on the
patient’s ability to make a decision (Meade & Howser, 1992).
If approached at time of diagnosis, participants may be so
stressed that they cannot make a decision. Approaching the
patient two to four weeks after the initial diagnosis of breast
cancer is less stressful. Patients become more interested when
physicians introduce the study during the presentation of treat-
ment options (Lengacher, 2000). If the researcher takes time
to explain the trial during the consent process, decreased at-
trition from the trial may occur. Sometimes, the complexity
and legal language can increase anxiety and decrease under-
standing. Providing complex information can lead to poor
understanding and miscommunication (Meade, 1999). Stud-
ies have shown that understanding the average consent form
requires at least a high school education (Baker & Taub, 1983;
Grundner, 1980; Meade & Howser; Morrow, 1980). Contin-
ued examination related to how individuals perceive clinical
trials is critical.
Physician Factors
Physician factors that can affect successful trial participa-
tion are physician and staff support, philosophy of the physi-
cian, equitable compensation, and community referrals. A
major reason for inadequate accrual has been the decision of
physicians not to enroll eligible patients (Benson et al., 1991;
Winn, 1994). A study reported that the main reason reported
for nonparticipation by patients was the advice received from
the primary-care physician (Henzlova, Blackburn, Bradley, &
Rogers, 1994). Medical oncologists identified inconvenience
to patients, excessive physician time, and lack of support for
follow-up as specific reasons for nonaccrual (Benson et al.).
Some physicians do not like communicating uncertainty about
the effectiveness of the treatment for fear of being construed
as lacking knowledge regarding treatment and disease
(Schain, 1994). A physician’s philosophy about patient care
can be a barrier (Schain). As indicated earlier, the complex-
ity of the design also has been identified as a barrier to partici-
pation by physicians (Tangrea, 1997). Effective clinical inves-
tigators integrate the role of the primary-care provider with
that of a research scientist (Taylor & Kelner, 1987). Lack of
compensation to the physician for time spent evaluating pa-
tients prior to enrollment and absence of reimbursement of
physicians’ fees, laboratory fees, and diagnostic tests are other
barriers (Mansour, 1994; Tangrea). Often, these costs are not
covered by the government or insurance company (Tangrea).
Community physician referrals are influenced by the expe-
riences, beliefs, and attitudes of the community physician.
Community physicians first must be made aware of trials and
then reassured that they will not lose control of or contact with
patients (Mansour, 1994). Trust must be enhanced, particu-
larly with minority patients and physicians. Community phy-
sicians should be given as much detail and information as
possible related to the intervention protocol so they can assist
LENGACHER – VOL 28, NO 7, 2001
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with the management of problems, particularly if patients live
a distance from the hospital that is conducting the clinical trial
(Tangrea, 1997).
Strategies for Success
Once the barriers are understood, strategies for overcoming
them can be identified in order for accrual to be successful.
Examination of successful programs and interventions related
to clinical trials with widely diverse populations need to be
examined. Communication with primary-care physicians and
a caring attitude on the part of researchers is critical. Needs of
the elderly will have to be considered and met because of the
need to increase enrollment of the elderly in clinical trials.
A number of strategies for successful clinical trials can be
implemented. Based on a literature review and as identified in
the model, there should be justification for complex designs.
This justification can be monitored by the principal investiga-
tor, the institutional review board, or the institution where the
research is implemented. Knowledge of general and specific
participant factors can assist researchers in developing strat-
egies that will increase accrual, consider the needs of the eld-
erly, and provide specific financial support for transportation.
Given, Keilman, Collins, and Given (1990) support the
strategy of fostering a bond between participants and study
personnel. Recognition can be given for participation—formal
thank-you letters, handwritten notes from nurses or project
managers during the study, and a verbal thank you after par-
ticipation. Making contact with patients and accommodating
their needs may be critical to participation. In addition, com-
pensation for participation can assist the patient with indirect
costs. If scheduling problems occur, the research team should
assist patients in arranging times that are convenient for both.
Several strategies have been identified to increase minority re-
cruitment and retention. Fully defining the target population,
involving members of the target population in planning ef-
forts, taking the message to the target population, giving
something back to the community, and providing education to
the community during the informed consent process are criti-
cal for enrollment and adherence. Time, education, and a car-
ing attitude during the informed consent process also are im-
portant. Communication among providers and providing
information related to treatment and the clinical trial will im-
prove attitudes of primary-care providers and follow-up care
for patients. Frequent contacts with physicians and providers
are important during a time when downsizing has been the
standard (Motzer, Reynolds-Moseley, & Lewis, 1997). In ad-
dition, trials should be conducted in facilities that are viewed
to be trustworthy and that will provide appropriate compen-
sation to patients and physicians (Robinson, Ashley, &
Haynes, 1996).
Future studies need to be conducted to examine the effects
of strategies to overcome these common barriers to clinical
trial accrual. Results of these studies will facilitate successful
nursing-initiated clinical trials and multidisciplinary clinical
trials.
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